Zinc Oxide
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Zinc Oxide: From Skin Conditions (Tinea, Dermatitis, Burns) to Acne
One-Sentence Summary
Zinc oxide is a topical skin protectant and astringent, originally used for skin conditions such as tinea infections, dermatitis, burns and hemorrhoids. The TxGNN model predicts it may be effective for Acne (disease), but there are no registered clinical trials and only 3 publications (one general review, one preclinical study, one small clinical study), so the evidence is weak and this remains a research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the US license records; the knowledge graph lists tinea pedis, tinea corporis, dermatitis, cutaneous candidiasis, pityriasis versicolor, hemorrhoid, proctitis, burn and injury |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (no currently valid license) |
| Number of NDAs | 2 (both cancelled) |
| Recommended Decision | Hold (research question only) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for zinc oxide. The reasoning below rests on general pharmacology, not on a defined drug mechanism.
Zinc ions have mild antibacterial activity, including against Cutibacterium acnes, along with anti-inflammatory effects, and they may reduce sebum-related inflammation. Zinc oxide is already used topically in dermatology as a skin protectant, so acne sits in the same therapeutic area as its existing indications (dermatitis, cutaneous infections).
The high TxGNN score (99.86%) is a computational prediction only. The supporting literature is limited: one nanoparticle review mentions nano-preparations under investigation for acne, one preclinical microneedle study involves zinc-related nanomaterials, and one small clinical study of mild catamenial acne does not clearly establish a role for zinc oxide.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21342155 | 2011 | Review | International Journal of Dermatology | Overview of engineered nanoparticles such as zinc oxide and titanium dioxide in skin care. Nano-preparations are under investigation for acne vulgaris, condyloma acuminata, atopic dermatitis and other conditions. |
| 36888703 | 2023 | Preclinical/Experimental | Science Advances | Ultrasound-responsive microneedle patch delivering nanoparticles for P. acnes infection, as an antibiotic-free acne approach. Zinc oxide’s role is unclear (the nanoparticles are zinc porphyrin-based). |
| 15536660 | 2004 | Clinical study (split-face, small, likely non-RCT) | Skin Research and Technology | Assessment of mild inflammatory catamenial acne in young women. The design and the role of zinc oxide cannot be confirmed from the available information. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M016 (cancelled) | zinc oxide 20% (Bionpharma Inc) | Ointment | Not stated |
| M020 (cancelled) | Mineral Sunscreen For Face and Body (Skin Philosophy by Kelly) | Cream | Not stated |
Both licenses are cancelled, so no valid US authorization currently exists in the data compiled for this report.
Safety Considerations
The knowledge graph links zinc oxide to contraindication edges for several conditions. This comes from graph relationships, not from label text, and should be treated as a signal for review, not as confirmed contraindications:
- Cardiovascular: hypertensive disorder, hypertension, coronary artery disease, sudden cardiac arrest, heart conduction disease
- Metal and iron metabolism: hereditary hemochromatosis, hemosiderosis, iron metabolism disease, Wilson disease
- Haematological: sickle cell anemia, hereditary persistence of fetal hemoglobin
- Endocrine: hyperthyroidism, Graves disease, thyrotoxicosis
- Other: benign prostatic hyperplasia, primary hyperoxaluria, anxiety
No drug-interaction records were found. For package-insert warnings and contraindications, please refer to the product labeling.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a computational score and general zinc pharmacology. There are no registered trials, the literature is indirect (a review, a preclinical study and a small study of unclear design), and no US license is currently valid. This makes it a research question, not a candidate ready for development.
To proceed, the following is needed:
- Mechanism of action data for zinc oxide, to support the link to acne
- Package-insert warnings and contraindications, to allow safety screening
- Controlled clinical evidence (for example, a randomized trial of topical zinc oxide in acne)
- A route and formulation compatibility assessment for acne use
- Review of the knowledge-graph contraindication signals against topical use
Other Predictions (For Reference)
The other four predictions have no clinical trials or literature and are all rated L5 (model prediction only) with a Hold recommendation:
| Predicted Indication | TxGNN Score | Note | |——|——|——| | Anorectal stricture | 99.46% | Only a weak contextual link to existing anorectal uses; a topical protectant is unlikely to address fibrotic narrowing | | Anal polyp | 99.31% | Only anatomical proximity; no known effect on polyp growth | | Papillary conjunctivitis | 99.14% | Speculative; zinc oxide is not formulated for ocular use, so tolerability is a concern | | Postinfectious vasculitis | 99.02% | No plausible pathway from a topical agent to a systemic immune-mediated disease |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.